Therapeutic cloning to become a reality for Britain

The potential therapeutic benefits of research on human embryos areenormous and outweigh the ethical and safety concerns, the UKgovernment decided this week.

Written byJoanna Lyford
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

LONDON, August 18. A mixture of horror and excitement greeted the British government's decision this week to allow stem cell research and therapeutic cloning. For most scientists, the risk–benefit balance is clearly weighted in favour of such research, and the decision heralds a new era of therapeutic possibilities. But for many people in Britain it smacks of eugenics and meddling with the sanctity of life. So what is all the fuss about?

On Wednesday Tony Blair's government endorsed the conclusions of an expert committee led by Liam Donaldson, the chief medical officer, that embryonic stem cells — primordial cells that can differentiate into any mature cell type given the right conditions — have "enormous potential" to create new forms of treatment for currently incurable diseases. At present, research on human embryos up to 14 days old is permitted for a handful of specific purposes related to infertility. Animal studies, mainly ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies